Securities code: Jafron Biomedical Co.Ltd(300529) securities abbreviation: Jafron Biomedical Co.Ltd(300529) Announcement No.: 2022044 bond Code: 123117 bond abbreviation: Jianfan convertible bond
Jafron Biomedical Co.Ltd(300529)
First quarter report 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. Important content tips: 1 The board of directors, the board of supervisors, directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2. The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report. 3. Whether the first quarter report has been audited □ yes √ No 1. Main financial data (I) whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 6973554093557890135198 20.46%
Net profit attributable to shareholders of listed company (yuan): 3352074631028330590408 18.32%
Net profit attributable to shareholders of listed company after deducting non recurring loss of 3225945191727378053971 17.83% (yuan)
Net cash flow from operating activities (yuan) 1280669027623472014772 – 45.44%
Basic earnings per share (yuan / share) 0.42 0.35 20.00%
Diluted earnings per share (yuan / share) 0.41 0.35 17.14%
Weighted average return on net assets 9.50% – 0.61%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 509484778316481010212072 5.92%
Owner’s equity attributable to shareholders of listed company (yuan): 369384731782335885769759 9.97%
（2） Non recurring profit and loss items and amount √ applicable □ not applicable
Unit: Yuan
Description of the amount of the project in the current reporting period
Gains and losses on disposal of non current assets (including the write off part of the provision for asset impairment) 19914351
Government subsidies included in the current profits and losses (closely related to the company’s normal business, in line with the national policy 457498743)
(except for government subsidies that are continuously enjoyed according to policies and certain standards, quotas or quotas)
In addition to the effective hedging business related to the normal business of the company, it holds trading financial assets
Gains and losses from changes in fair value of assets and trading financial liabilities, and disposal of trading financial assets 1067139366
Investment income from assets, trading financial liabilities and available for sale financial assets
Other non operating income and expenses other than the above -61091340
Less: income tax impact 221723572
Influence amount of minority shareholders’ equity (after tax) 443155
Total 1261294393–
Details of other profit and loss items that meet the definition of non recurring profit and loss: □ applicable √ not applicable. The company does not have details of other profit and loss items that meet the definition of non recurring profit and loss. Description of defining the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items □ applicable √ not applicable the company does not define the non recurring profit and loss items listed in the explanatory announcement on Information Disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items.
（3） Changes and reasons of main accounting data and financial indicators √ applicable □ not applicable
Unit: Yuan
1、 Balance sheet items
Description of increase or decrease exceeding 30% from March 31, 2022 to December 31, 2021
range
Trading financial assets – 15001498501 – 100.00% are mainly due to the redemption of financial products held at the end of last year.
Notes receivable 25498673663896530845 – 34.56% is mainly due to the discount of notes receivable held at the end of last year in the current period.
Accounts receivable 3746345994826908995821 39.22% was mainly due to the increase of sales revenue in the current period.
The advance payment 108863461856313459976 72.43% was mainly due to the increase of purchase advance payment in this period.
Other receivables 1318008872631703367 108.64% were mainly due to the increase of employee reserve fund in the current period compared with the end of the previous year.
4134531170530115480790 37.29% of the projects under construction are mainly due to the increase of investment in engineering base and production line.
The long-term deferred expenses were 56854363163595200691 and 58.14%, mainly due to the completion of some decoration projects of the company in this period.
Contract liabilities 6328447152064854747 – 69.35% were mainly due to the receipt of customers’ advance payment in the previous period and the billing and delivery in the current period.
Other current liabilities 82269813237967080 – 65.43% were mainly due to the receipt of customers’ advance payment in the previous period and the billing and delivery in the current period.
Deferred income tax liabilities 10462029772916509 are mainly due to the derecognition of an investment in other equity instruments in the current period and the recovery of 43.48% of the investment amount.
Other comprehensive income 592848348411919823 was mainly due to the derecognition of an investment in other equity instruments and the recovery of 43.92% of the investment funds in the current period.
2、 Income statement items
Project from January to March 2022 and description of changes in excess of 30% from January to March 2021
range
The R & D expenses were 4077164913, 2090546560 and 95.03%, mainly due to the new R & D projects in the previous year and the continuous investment expenses in the current period.
Financial expenses 95775362399851414 123.95% were mainly due to the withdrawal of interest expenses of convertible bonds in the current period.
Other income 482807271363289459 32.90% was mainly due to the increase of government subsidies received in the current period compared with the same period of last year.
The investment income (loss) was 1068637867781192979 36.80%, which was mainly due to the increase in the income of financial products in the current period.
“-“)
The change in fair value received -1498501 — mainly due to the redemption of financial products of the previous year in the current period.
Profit (loss with “-“)
(fill in)
The income (loss) from asset disposal was 19914351 – mainly due to the disposal of fixed assets in the current period.
(loss is indicated with “-“)
Plus: the non operating income was 4281279 and 13796146 – 68.97%, mainly due to the scrapping of fixed assets in the previous period.
Less: non operating expenses 6537261938176679 71.24%, mainly due to the increase in public welfare donations in the current period compared with the previous period.
The profit and loss of minority shareholders was -81713693 -52154629, mainly due to the increase of – 56.68% in the loss of non wholly owned subsidiaries in the current period compared with the previous period.
3、 Cash flow statement items
Project from January to March, 2022 to January to March, 2021
The tax refund received was 25102432 and 4754576, which was mainly due to the 427.96% increase in VAT refund received in the current period compared with the previous period.
Purchase goods and accept labor
